Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Deferred Taxes of -$65.3 million for Q1 2026, up 65.92% year-over-year from -$39.4 million in Q1 2025, and down 314.1% quarter-over-quarter from $30.5 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Deferred Taxes history runs 16 years deep, the most recent figure standing at -$65.3 million for Q1 2026.
- In Q1 2026, Deferred Taxes rose 65.92% year-over-year to -$65.3 million; the TTM figure through Mar 2026 stood at -$384.5 million (down 0.63% YoY), while the FY2025 annual figure was -$510.8 million, down 46.44% from the prior year.
- Deferred Taxes for Q1 2026 stood at -$65.3 million, down from $30.5 million in the prior quarter.
- The five-year high for Deferred Taxes was $148.1 million in Q4 2022, with the low at -$235.9 million in Q3 2025.
- The 5-year median for Deferred Taxes is -$118.8 million (2024), against an average of -$102.2 million.
- The sharpest annual moves came in 2022 and 2023: Deferred Taxes soared 453.46% in 2022, then plunged 821.95% in 2023.
- Vertex Pharmaceuticals' Deferred Taxes stood at $148.1 million in 2022, then tumbled by 188.45% to -$131.0 million in 2023, then soared by 139.39% to $51.6 million in 2024, then sank by 40.89% to $30.5 million in 2025, then sank by 314.1% to -$65.3 million in 2026.
- Business Quant data shows VRTX's Deferred Taxes at -$65.3 million in Q1 2026, $30.5 million in Q4 2025, and -$235.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.70 Mn |
| Mar 31, 2026 | -65.30 Mn |
| Dec 31, 2025 | 30.50 Mn |
| Sep 30, 2025 | -235.90 Mn |
| Jun 30, 2025 | -113.80 Mn |
| Mar 31, 2025 | -191.60 Mn |
| Dec 31, 2024 | 51.60 Mn |
| Sep 30, 2024 | -123.30 Mn |
| Jun 30, 2024 | -118.80 Mn |
| Mar 31, 2024 | -158.30 Mn |
| Dec 31, 2023 | -131.00 Mn |
| Sep 30, 2023 | -115.50 Mn |
| Jun 30, 2023 | -176.60 Mn |
| Mar 31, 2023 | -113.40 Mn |
| Dec 31, 2022 | 148.10 Mn |
| Sep 30, 2022 | -182.30 Mn |
| Jun 30, 2022 | -229.40 Mn |
| Mar 31, 2022 | -12.30 Mn |
| Dec 31, 2021 | -41.90 Mn |
| Sep 30, 2021 | 68.20 Mn |